Oct282019UncategorizedCategory: UncategorizedBy Charlotte Maddalena28 October 2019Leave a comment Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development OfficerNextNext post:Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapiesRelated PostsORPHELIA Pharma announces Orphan Drug Designation granted by FDA for temozolomide in the treatment of neuroblastoma10 December 2019ORPHELIA Pharma recrute un/une Assistant(e) administrative, commercial(e) et comptable9 December 2019ORPHELIA Pharma Recrute un/une Medical Science Liaison France et Europe9 December 2019ORPHELIA Pharma recrute un/une Responsable marchés publics France et Europe9 December 2019Newsletter november 20194 December 2019Two new projects supported by our Foundation4 December 2019
ORPHELIA Pharma announces Orphan Drug Designation granted by FDA for temozolomide in the treatment of neuroblastoma10 December 2019
ORPHELIA Pharma recrute un/une Assistant(e) administrative, commercial(e) et comptable9 December 2019
